On a YoY basis, the dollar revenue for the company showed a decline of 4.8% in CC terms and on a sequential basis it declined by 2% in CC terms. The decline is primarily attributed to weak macro environment, slower conversion of TCV into revenues and slowdown in the European market. The health segment continue to outperform with (7.1% YoY CC), followed by the Technology segment (1.7% YoY CC).